Overview

Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer

Status:
Completed
Trial end date:
2020-10-08
Target enrollment:
Participant gender:
Summary
The aim is to assess the relative efficacy of S-1 de-escalation therapy vs. continuation of chemotherapy after induction therapy in patients with metastatic esophagogastric cancer in terms of overall survival.
Phase:
Phase 2
Details
Lead Sponsor:
AIO-Studien-gGmbH
Collaborators:
Nordic Pharma SAS
Taiho Pharmaceutical Co., Ltd.
Treatments:
Capecitabine
Cisplatin
Docetaxel
Epirubicin
Fluorouracil
Leucovorin
Levoleucovorin
Oxaliplatin